Pharmaceutical

EC approves BMS’ Camzyos for hypertrophic cardiomyopathy

The European Commission has approved Bristol Myers Squibb’s Camzyos to treat symptomatic obstructive hypertrophic cardiomyopathy.

Jun 27, 2023 - 20:00
EC approves BMS’ Camzyos for hypertrophic cardiomyopathy
The European Commission has approved Bristol Myers Squibb’s Camzyos to treat symptomatic obstructive hypertrophic cardiomyopathy.
Read the original article

Tags:

Previous Article

Tonix to acquire Upsher-Smith’s migraine products

Next Article

Vertex and Lonza to establish T1D cell therapy manufacturing facility

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

The White House has a pharmacy — and it was a mess, a new investigation found

The White House has a pharmacy — and it was a mess, a n...

Jan 24, 2024

FDA accept NextPoint Therapeutics IND for HHLA2 targeting mAb

FDA accept NextPoint Therapeutics IND for HHLA2 targeti...

Dec 8, 2023

He was named a MacArthur ‘genius’ fellow for research on gene regulation, but still has imposter syndrome

He was named a MacArthur ‘genius’ fellow for research o...

Oct 14, 2023